Subject 1: Scan 1 (4/3/02 - 4/22/03)

Fig. 1. Improvement in bone density a subject (female, age 59 years) taking OsteoPhase calcium balancing formula. Subject volunteered for a 4 month safety evaluation period after a preliminary scan (DEXA) revealed the presence of mild osteopenia. Subject completed the safety evaluation period with no side effects or problems with formula. Subject returned to be retested 8 months after the end of the evaluation period (12 months after first scan). The second scan revealed that BMD (g/cm2) had increased from an initial score of .671 to .712 (yellow highlighted area), indicating a 6.1% increase in bone density.

All contents Copyright © 2006 Tango Advanced Nutrition, Inc. All rights reserved. AllerPhase®, FemmePhase®, OsteoPhase®, Tango®, Pure Tango® and PriaPlex® are registered trademarks of Tango Advanced Nutrition, Inc.

The content provided by this site is for informational purposes only and has not been approved by the U.S. FDA. This site is not intended to provide personal medical advice, which should be obtained from a medical professional.